Page Title
Drug Development Pipeline
Trikafta (elexacaftor/tezacaftor/ivacaftor)
Status
To PatientsTherapeutic Approach
Restore CFTR Protein
Trikafta (elexacaftor/tezacaftor/ivacaftor) is a combination therapy combining three CFTR modulators. Elexacaftor and tezacaftor are CFTR correctors, a type of modulator designed to fix the defective CFTR protein so that it can move to the proper place on the cell surface. Ivacaftor is a potentiator. Once CFTR protein reaches the cell surface, potentiators help facilitate the opening of the chloride channel to allow chloride and sodium (salt) to move in and out of the cell.
Status
Trikafta has been approved for people with CF ages 2 and older who have any mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that produces a CFTR protein.
People with cystic fibrosis or their loved ones who want to learn whether they are eligible for a CFTR modulator should talk with their care team. Additional information about treatment eligibility is also available through Vertex’s Treatments Finder.
An ongoing observational study will look at the effects of Trikafta on growth in young children with CF.
Sponsor
This program is sponsored by Vertex Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation. This program was conducted within the Therapeutics Development Network (TDN).
Recent Trikafta (elexacaftor/tezacaftor/ivacaftor) Studies
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More